Diabetes drug dapagliflozin could also be beneficial for patients with progressive liver disease, a clinical trial has shown.

Around 3,000 lives could be saved and 5,500 hospital admissions prevented each year by changes to how people are treated for heart failure, according to a watchdog. New draft guidelines from the ...

New guidelines for treating heart failure could save 3,000 lives and prevent 5,500 hospital admissions every year, according ...

A drug commonly used to treat type 2 diabetes may also help improve a serious liver condition, according to a new clinical ...

For patients with MASH, treatment with dapagliflozin is beneficial for improvement of MASH without worsening of fibrosis and for improvement of fibrosis without worsening of MASH.

A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type 2 diabetes, significantly improved liver inflammation and scarring in ...

Key Takeaways A diabetes drug can help treat fatty liver diseaseDapagliflozin helped lower fat levels and prevent scarring in ...

A recent Chinese clinical trial published in The BMJ reveals that dapagliflozin, a type 2 diabetes drug, shows promise in ...

Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

ANSWER: Both prediabetes and diabetes are metabolic abnormalities in which the body cannot use sugar properly. There are ...

Scientists at Thomas Jefferson University have made an exciting discovery that could improve the lives of many people with Type 2 diabetes. Their research shows that using two drugs ...